spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  cervical dystonia 

 HSMN NewsFeed - 2 May 2022
Supernus Announces FDA Approval of Qelbree(R) for the Treatment of ADHD in Adults
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Dec 2021
Healis Therapeutics announces mission to deliver new class of neuromuscular treatments in psychiatry
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2020
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX(R) (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 18 Nov 2019
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 3 Jul 2015
Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.
Biopharmaceuticals Drug Delivery Dermatology Personnel
 HSMN NewsFeed - 5 Nov 2014
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 11 Jul 2014
Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1
Biopharmaceuticals Dermatology Distribution
 HSMN NewsFeed - 5 Feb 2014
Ipsen announces clinical results of Dysport(R) Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW(1)
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2013
Neurotech Pharmaceuticals Adds Ophthalmic Leaders to Advance Groundbreaking Sight-Saving Therapies
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 13 Apr 2012
BOTOX(R) Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 13 Aug 2010
US WorldMeds Acquires Solstice Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 2 Aug 2010
FDA Approves Merz Pharmaceuticals' Xeomin(R) (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 9 Jul 2010
BOTOX(R) Receives First Authorisation in UK as Preventative Treatment in Chronic Migraine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Jun 2010
Ipsen: Encouraging results of GuidAge(R), large scale European trial conducted in the prevention of Alzheimer's Dementia
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Oct 2009
Ipsen Announces the Launch of Dysport(R) (abobotulinumtoxinA) in the United States for the Treatment of Cervical Dystonia
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2009
FDA Approves Dysport(TM) for Therapeutic and Aesthetic Uses
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Feb 2009
The Health Authorities of 15 European Countries Give a Collective Green Light to Azzalure For the Treatment of Glabellar Lines, Paving the Way for National Marketing Authorizations
Biopharmaceuticals Regulatory Dermatology
 HSMN NewsFeed - 11 Sep 2008
Allergan Announces Positive Top-Line Results from Phase III BOTOX(R) Headache Program
Biopharmaceuticals
 HSMN NewsFeed - 8 Feb 2008
Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Biopharmaceuticals
 HSMN NewsFeed - 31 Jan 2008
Ipsen: FDA Accepts for Filing a Biologics License Application (BLA) for Dysport(R) in Cervical Dystonia
Biopharmaceuticals
 HSMN NewsFeed - 21 Dec 2007
Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2007
Ipsen Grants Galderma Exclusive Rights to Promote and Distribute Dysport(R) in Aesthetic Medicine and Dermatological Indications in Brazil, Argentina and Paraguay
Biopharmaceuticals Distribution Dermatology
 HSMN NewsFeed - 11 Oct 2007
Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 3 Jul 2007
Mentor Announces Initial Patient Injections in Phase III Study for PurTox(R) Botulinum Toxin Type A
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 15 May 2007
Solstice Neurosciences, Inc. Announces Commercialization Agreement
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2006
Deep Brain Stimulation Benefits Primary Dystonia Sufferers Says Study Published in New England Journal of Medicine
Devices Neurology
 HSMN NewsFeed - 8 Nov 2006
Solstice Neurosciences Raises $85 Million in Private Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 May 2006
Mentor Begins U.S. Phase 1 Study of Its Botulinum Toxin Product for Spasmodic Torticollis/Cervical Dystonia
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
cervical dystonia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.